Table 2.
Effect of paracetamol use on BHR, lung function and asthma control
| Baseline |
Week 12 |
Difference (adjusted for baseline) | |||
|---|---|---|---|---|---|
| Paracetamol N=36 |
Placebo N=58 |
Paracetamol N=31 |
Placebo N=54 |
||
| Log 2 PC20 (mg/mL) | 1.30 (1.50) | 1.09 (1.96) | 0.62 (2.09) | 1.07 (2.36) | −0.48 (−1.28 to 0.32) p=0.24* |
| FEV1 (L) | 3.06 (0.73) | 3.05 (0.83) | 3.01 (0.74) | 3.07 (0.86) | −0.07 (−0.15 to 0.01) p=0.08 |
| ACQ score | 0.81 (0.47) | 0.93 (0.59) | 0.88 (0.56) | 1.03 (0.71) | −0.04 (−0.27 to 0.18) p=0.71 |
| Mean morning peak flow (L/min) | 424.0 (83.8) | 419.5 (92.3) | 417.1 (82.3) | 417.5 (85.9) | −8.6 (−26.7 to 9.5) p=0.35 |
| PEFvar (%) | 19.0 (9.3) | 22.2 (10.5) | 20.4 (10.3) | 21.7 (11.7) | 0.21 (−4.3 to 4.8) p=0.93 |
Numbers are mean (SD).
*Difference in doubling doses.
ACQ, Asthma Control Questionnaire; BHR, bronchial hyper-responsiveness testing; FEV1, forced expiratory volume in one second; PC20, provocation concentration of methacholine causing a 20% fall in FEV1; PEFvar, PEF variability (measured as amplitude as a percentage of the mean).